ALKERMES PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.4 USD | +0.82% |
|
-2.58% | -15.65% |
| May. 23 | Cantor Fitzgerald Adjusts Alkermes Price Target to $48 From $43, Maintains Overweight Rating | MT |
| May. 02 | UBS Adjusts Price Target on Alkermes to $21 From $23, Maintains Sell Rating | MT |
Financials (USD)
| Sales 2024 * | 1.5B | Sales 2025 * | 1.51B | Capitalization | 3.96B |
|---|---|---|---|---|---|
| Net income 2024 * | 336M | Net income 2025 * | 350M | EV / Sales 2024 * | 2.19 x |
| Net cash position 2024 * | 663M | Net cash position 2025 * | 1.03B | EV / Sales 2025 * | 1.94 x |
| P/E ratio 2024 * |
12.1
x | P/E ratio 2025 * |
12
x | Employees | 2,100 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.07% |
More Fundamentals
* Assessed data
More news
Latest transcript on Alkermes plc
More recommendations
More press releases
| 1 day | +0.82% | ||
| 1 week | -2.58% | ||
| 1 month | -4.65% | ||
| 3 months | -21.19% | ||
| 6 months | -3.07% | ||
| Current year | -15.65% |
1 week
23.14
24.32
1 month
23.1425.29
Current year
23.1432.88
1 year
22.0133.71
3 years
21.2433.71
5 years
11.9833.71
10 years
11.9880.71
| Managers | Title | Age | Since |
|---|---|---|---|
Richard Pops
CEO | Chief Executive Officer | 62 | 91-01-31 |
Blair Jackson
DFI | Director of Finance/CFO | 51 | 98-12-31 |
Shane Cooke
PSD | President | 61 | 11-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Richard Pops
CEO | Chief Executive Officer | 62 | 91-01-31 |
Nancy Snyderman
BRD | Director/Board Member | 72 | 16-05-25 |
Brian McKeon
BRD | Director/Board Member | 61 | 20-12-09 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 15.32% | 254 M€ | +13.69% | - | |
| 2.65% | 1 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 23.4 | +0.82% | 3,159,599 |
| 24-05-30 | 23.21 | -0.34% | 1,478,576 |
| 24-05-29 | 23.29 | -1.94% | 2,075,783 |
| 24-05-28 | 23.75 | -1.12% | 1,483,349 |
| 24-05-24 | 24.02 | +0.08% | 1,868,835 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
23.4
USD
Average target price
34.27
USD
Spread / Average Target
+46.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.65% | 3.96B | |
| +43.36% | 54.64B | |
| -5.31% | 39.92B | |
| +37.52% | 38.82B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +0.04% | 12.16B | |
| +25.12% | 12.21B | |
| +26.04% | 11.94B |
- Stock Market
- Equities
- ALKS Stock
